

JosÃ© Palacios

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3167714/publications.pdf>

Version: 2024-02-01

52
papers

1,210
citations

394421

19
h-index

395702

33
g-index

55
all docs

55
docs citations

55
times ranked

2624
citing authors

#	ARTICLE	IF	CITATIONS
1	RNA SARS-CoV-2 Persistence in the Lung of Severe COVID-19 Patients: A Case Series of Autopsies. <i>Frontiers in Microbiology</i> , 2022, 13, 824967.	3.5	18
2	Acute Dyspnea and Hemoptysis in an 84-Year-Old Man With Multiple Comorbidities. <i>Chest</i> , 2022, 161, e97-e101.	0.8	1
3	Comparison of the Idylla [®] MSI assay with the Promega [®] MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> . 2022, 480, 1031-1039.	2.8	6
4	Cytological and molecular characterization of secretory breast carcinoma. <i>Diagnostic Cytopathology</i> , 2022, , .	1.0	2
5	Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. <i>Cancers</i> , 2022, 14, 1151.	3.7	5
6	Impact of the COVID-19 pandemic on pathology training: a survey among Spanish residents. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 505-509.	2.8	3
7	Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 233.	3.7	4
8	Pulmonary vascular proliferation in patients with severe COVID-19: an autopsy study. <i>Thorax</i> , 2021, 76, 1044-1046.	5.6	12
9	MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.. <i>Journal of Clinical Oncology</i> , 2021, 39, 558-558.	1.6	0
10	Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7398.	4.1	13
11	Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer: A Europe-Wide External Quality Assessment. <i>Cancers</i> , 2021, 13, 4718.	3.7	6
12	Late Cardiac Pathology in Severe Covid-19. A Postmortem Series of 30 Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 748396.	2.4	9
13	Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. <i>Cancers</i> , 2021, 13, 5416.	3.7	7
14	Immune-related gene expression signatures: a step forward in the stratification of patients with ovarian clear cell carcinoma. <i>Journal of Pathology</i> , 2021, , .	4.5	0
15	Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma. <i>Cancers</i> , 2020, 12, 1832.	3.7	30
16	Next generation sequencing to decipher concurrent loss of PMS2 and MSH6 in colorectal cancer. <i>Diagnostic Pathology</i> , 2020, 15, 84.	2.0	3
17	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (ProTYPE). <i>Clinical Cancer Research</i> , 2020, 26, 5411-5423.	7.0	43
18	Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers. <i>Cancers</i> , 2020, 12, 1578.	3.7	5

#	ARTICLE	IF	CITATIONS
19	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). <i>Oncologist</i> , 2020, 25, 745-e1265.	3.7	25
20	High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features. <i>Cancers</i> , 2019, 11, 74.	3.7	33
21	Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study. <i>Human Pathology</i> , 2018, 72, 100-106.	2.0	28
22	Histological changes secondary to wire coil placement in breast tissue and lymph nodes. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 285-291.	2.8	2
23	Pleomorphic lobular carcinoma of the breast with osteoclast-like giant cells: a case report and review of the literature. <i>Diagnostic Pathology</i> , 2018, 13, 62.	2.0	11
24	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 250-261.	3.0	70
25	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
26	Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes. <i>British Journal of Cancer</i> , 2017, 117, 1048-1062.	6.4	12
27	Treating <i>KRAS</i> -mutant NSCLC: latest evidence and clinical consequences. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 589-597.	3.2	33
28	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. <i>Oncologist</i> , 2017, 22, 1301-1308.	3.7	13
29	¹⁸ F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. <i>Clinical Cancer Research</i> , 2017, 23, 1432-1441.	7.0	32
30	Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer. <i>Journal of Pathology</i> , 2017, 241, 475-487.	4.5	42
31	CD8 ⁺ TILs in early stage epithelial ovarian cancer: A GEICO study. <i>Journal of Clinical Oncology</i> , 2017, 35, 5543-5543.	1.6	0
32	Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH. <i>Farmacia Hospitalaria</i> , 2017, 41, 688-691.	0.6	3
33	The <i>NER</i> -related gene <i>GTF2H5</i> predicts survival in high-grade serous ovarian cancer patients. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e7.	2.2	30
34	CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy. <i>Histopathology</i> , 2016, 69, 239-249.	2.9	12
35	High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. <i>Oncologist</i> , 2016, 21, 150-155.	3.7	35
36	Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. <i>Modern Pathology</i> , 2016, 29, 1390-1398.	5.5	80

#	ARTICLE	IF	CITATIONS
37	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. <i>Histopathology</i> , 2016, 68, 45-56.	2.9	37
38	Molecularly determined total tumour load in lymph nodes of stage Iâ€”II colon cancer patients correlates with high-risk factors. A multicentre prospective study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 385-394.	2.8	24
39	Necitumumab in squamous non-small-cell lung cancer: how to move forward?. <i>Annals of Oncology</i> , 2016, 27, 1374-1376.	1.2	0
40	Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E328-37.	7.1	41
41	A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS479-TPS479.	1.6	2
42	The nuclear corepressor 1 and the thyroid hormone receptor Î² suppress breast tumor lymphangiogenesis. <i>Oncotarget</i> , 2016, 7, 78971-78984.	1.8	15
43	Deletion at 6q24.2â€”26 predicts longer survival of highâ€”grade serous epithelial ovarian cancer patients. <i>Molecular Oncology</i> , 2015, 9, 422-436.	4.6	17
44	Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour. <i>Human Molecular Genetics</i> , 2015, 24, 2914-2922.	2.9	60
45	Prognostic factors in advanced gastric cancer after second-line treatment.. <i>Journal of Clinical Oncology</i> , 2015, 33, 201-201.	1.6	0
46	Clinicopathological Significance of Taz and VGLL1 Expression in Early Stage Ovarian Cancer. A study by Spanish Group for Ovarian Cancer Research (GEICO).. <i>Journal of Clinical Oncology</i> , 2015, 33, e16583-e16583.	1.6	0
47	A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. <i>Human Pathology</i> , 2014, 45, 2394-2403.	2.0	18
48	Nabrax: Neoadjuvant therapy of breast cancer with weekly single-agent nab-paclitaxelâ€”Final efficacy and biomarkers analysis of GEICAM 2011-02 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1051-1051.	1.6	3
49	MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e90524.	2.5	65
50	Central pathology review of early-stage ovarian carcinoma: Description and correlation with follow-upâ€”A study by the Spanish Group for Ovarian Cancer Research (GEICO).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5583-5583.	1.6	2
51	Survival surrogates in gastric cancer after first- and second-line chemotherapy treatment: A Spanish retrospective study from one institution.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15019-e15019.	1.6	0
52	Aurora kinases as prognostic biomarkers in ovarian carcinoma. <i>Human Pathology</i> , 2009, 40, 631-638.	2.0	35